Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera

Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera

We report a 55 year old woman with post-ET PV for 12 years, who experienced resolution of severe constitutional symptoms within 3 days, a marked reduction in splenomegaly and a rapid decline in the JAK2V617F allele burden during combination therapy with interferon-alpha2a and ruxolitinib. Within 4 w...

Full description

Bibliographic Details
Main Authors: M.E. Bjørn, K. de Stricker, L. Kjær, K. Ellemann, H.C. Hasselbalch
Format: Article
Language:English
Published: Elsevier 2014-01-01
Series:Leukemia Research Reports
Subjects:
Polycythemia vera
JAK2V617F-allele burden
Combination therapy
Interferon
Ruxolitinib
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048914000107

Similar Items

Similar Items